Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.

Molecular oncology - 1 Aug 2020

Fan Yun, Qiu Jinrong, Yu Ruoying, Cao Ran, Chen Xiaoxi, Ou Qiuxiang, Wu Xue, Shao Yang W, Nagasaka Misako, Zhang Jiexia, Ou Sai-Hong Ignatius

Abstract excerpt

Transmembrane domain (TMD) mutations of ERBB2 have previously been reported in lung cancer patients in addition to well-studied kinase domain (KD) mutations, which may stabilize ERBB2 heterodimerization with other EGFR family members and favor a kinase active conformation. However, the frequency and clinical significance of ERBB2 TMD mutations in Chinese population is unknown. We prospectively analyzed the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Gene Amplification

Share to Protein Domains

Share to Protein Multimerization

Share to Receptor, ErbB-3

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 32478891
DOI: 10.1002/1878-0261.12733
PMCID: PMC7400783

Genes

ERBB2
EGFR
ERBB3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.PMID 32478891Read ↗

ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China.Semantic proximity Read ↗

Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.Semantic proximity Read ↗

Clinical and molecular characteristics, transcriptome, and drug efficacy of ERBB2 tyrosine kinase and non-tyrosine kinase mutations in non-small cell lung cancerSemantic proximity Read ↗

ERBB2-Activating Mutations and Co-Occurring Genomic Alterations Contribute to Disease Heterogeneity in Patients With ERBB2-Mutant Lung Cancer.Semantic proximity Read ↗

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Semantic proximity Read ↗

High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.Semantic proximity Read ↗

HER2 mutations in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients.Semantic proximity Read ↗

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.Semantic proximity Read ↗

Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.